This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Weksler, B. B. Articles by Levy, D. E. Search for Related Content PubMed PubMed Citation Articles by Weksler, B. B. Articles by Levy, D. E.

Stroke, Vol 16, 5-9, Copyright © 1985 by American Heart Association

ARTICLES

Effects of low dose aspirin on platelet function in patients with recent cerebral ischemia

BB Weksler, JL Kent, D Rudolph, PB Scherer and DE Levy

We tested the antiplatelet effects of low-dose aspirin in patients with occlusive cerebrovascular disease, because conventional dosage aspirin inhibits vascular synthesis of prostacyclin at the same time that it inhibits platelets. The effects on platelet function and thromboxane A2 synthesis of 40 mg of aspirin daily or 40 mg aspirin plus dipyridamole were measured in 23 patients starting within a week after the onset of cerebral ischemia. All patients had normal baseline platelet aggregation responses to four stimuli: arachidonate, epinephrine, adenosine diphosphate and collagen. The generation of thromboxane A2 by platelets, measured as serum thromboxane B2, was also normal. After 3 to 7 days of low dose aspirin therapy, platelet aggregation responses were suppressed to the extent observed with higher dosage aspirin. Serotonin release during platelet aggregation was inhibited by more than 95% and thromboxane B2 levels in clotted blood fell by more than 95%. Responses to aspirin treatment were similar in patients with transient ischemic attacks and in those with stroke and were also similar in both sexes. No differences in platelet responses were observed between patients receiving aspirin alone and aspirin plus dipyridamole. Thus 40 mg aspirin daily inhibited platelet responses as effectively as higher doses of aspirin in patients who had recent cerebral ischemia and showed a cumulative antiplatelet effect.

This article has been cited by other articles:

				C. Patrono, C. Baigent, J. Hirsh, and G. Roth Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 199S - 233S. [Abstract] [Full Text] [PDF]

				Authors/Task Force Members, J.-P. Bassand, C. W. Hamm, D. Ardissino, E. Boersma, A. Budaj, F. Fernandez-Aviles, K. A.A. Fox, D. Hasdai, E. M. Ohman, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology Eur. Heart J., July 1, 2007; 28(13): 1598 - 1660. [Full Text] [PDF]

				C. Patrono, B. Coller, G. A. FitzGerald, J. Hirsh, and G. Roth Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 234S - 264S. [Abstract] [Full Text] [PDF]

				J. W. Eikelboom and G. J. Hankey Aspirin resistance:a new independent predictor of vascular events? J. Am. Coll. Cardiol., March 19, 2003; 41(6): 966 - 968. [Full Text] [PDF]

				C. Patrono, B. Coller, J. E. Dalen, G. A. FitzGerald, V. Fuster, M. Gent, J. Hirsh, and G. Roth Platelet-Active Drugs : The Relationships Among Dose, Effectiveness, and Side Effects Chest, January 1, 2001; 119(1_suppl): 39S - 63S. [Full Text] [PDF]

				V. L. Feigin, G.J.E. Rinkel, A. Algra, M. Vermeulen, and J. van Gijn Calcium antagonists in patients with aneurysmal subarachnoid hemorrhage: A systematic review Neurology, April 1, 1998; 50(4): 876 - 883. [Abstract] [Full Text] [PDF]

				T. P. Lecompte, C. Lecrubier, C. Bouloux, M.-H. Horellou, J. Galleyrand, J.-P. Maffrand, and M. M. Samama Antiplatelet Effects of the Addition of Acetylsalicylic Acid 40 Mg Daily to Ticlopidine in Human Healthy Volunteers Clinical and Applied Thrombosis/Hemostasis, October 1, 1997; 3(4): 245 - 250. [Abstract] [PDF]

				M. T. Santos, J. Valles, J. Aznar, A. J. Marcus, M. J. Broekman, and L. B. Safier Prothrombotic Effects of Erythrocytes on Platelet Reactivity: Reduction by Aspirin Circulation, January 7, 1997; 95(1): 63 - 68. [Abstract] [Full Text]

				N. B. Fountain and D. A. Eberhard Primary angiitis of the central nervous system associated with cerebral amyloid angiopathy: Report of two cases and review of the literature Neurology, January 1, 1996; 46(1): 190 - 197. [Abstract] [Full Text] [PDF]

				L. B. Goldstein, A. J. Bonito, D. B. Matchar, P. W. Duncan, G. H. DeFriese, E. Z. Oddone, J. E. Paul, D. R. Akin, and G. P. Samsa US National Survey of Physician Practices for the Secondary and Tertiary Prevention of Ischemic Stroke : Design, Service Availability, and Common Practices Stroke, September 1, 1995; 26(9): 1607 - 1615. [Abstract] [Full Text]

				B. Aspey and M. Harrison Sex differences in the antithrombotic effectiveness of aspirin Vascular Medicine, September 1, 1990; 1(2): 113 - 119. [PDF]